Cudraxanthone D ameliorates psoriasis-like skin inflammation in an imiquimod-induced mouse model via inhibiting the inflammatory signaling pathways

Cited 3 time in scopus
Metadata Downloads
Title
Cudraxanthone D ameliorates psoriasis-like skin inflammation in an imiquimod-induced mouse model via inhibiting the inflammatory signaling pathways
Author(s)
N Kim; Soyoung Lee; J Kang; Y A Choi; Y H Jang; G S Jeong; S H Kim
Bibliographic Citation
Molecules, vol. 26, no. 19, pp. 6086-6086
Publication Year
2021
Abstract
Psoriasis is a chronic inflammatory skin disease accompanied by excessive keratinocyte proliferation. Corticosteroids, vitamin D3 analogs, and calcineurin inhibitors, which are used to treat psoriasis, have diverse adverse effects, whereas natural products are popular due to their high efficiency and relatively low toxicity. The roots of the Cudrania tricuspidata (C. tricuspidata) are known to have diverse pharmacological effects, among which the anti-inflammatory effect is reported as a potential therapeutic agent in skin cells. Nevertheless, its effectiveness against skin diseases, especially psoriasis, is not fully elucidated. Here, we investigated the effect of cudraxanthone D (CD), extracted from the roots the C. tricuspidata Bureau, on psoriasis using an imiquimod (IMQ)-induced mouse model and the tumor necrosis factor (TNF)-α/interferon (IFN)-γ-activated keratinocytes. IMQ was topically applied to the back skin of C57BL/6 mice for seven consecutive days, and the mice were orally administered with CD. This resulted in reduced psoriatic characteristics, such as the skin thickness and Psoriasis Area Severity Index score, and the infiltration of neutrophils in IMQ-induced skin. CD inhibited the serum levels of TNF-α, immunoglobulin G2a, and myeloperoxidase, and the expression of Th1/Th17 cells in splenocytes. In TNF-α/IFN-γ-activated keratinocytes, CD reduced the expressions of CCL17, IL-1β, IL-6, and IL-8 by inhibiting the phosphorylation of STAT1 and the nuclear translocation of NF-kB. Taken together, these results suggest that CD could be a potential drug candidate for the treatment of psoriasis.
Keyword
Cudrania tricuspidata BureauCudraxanthone DPsoriasisImiquimodKeratinocytes
ISSN
1420-3049
Publisher
MDPI
DOI
http://dx.doi.org/10.3390/molecules26196086
Type
Article
Appears in Collections:
Jeonbuk Branch Institute > Functional Biomaterial Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.